Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19074158 | PLATELET DERIVATIVE COMPOSITIONS, AND PLURALITIES OF CONTAINERS CONTAINING SAME | March 2025 | April 2025 | Allow | 2 | 0 | 0 | No | No |
| 19066279 | EXOSOME SYSTEMS, PRODUCTS AND METHODS | February 2025 | April 2025 | Allow | 1 | 0 | 0 | No | No |
| 19065946 | MUSCLE TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING OF EXON 44 OF DYSTROPHIN IN A SUBJECT | February 2025 | May 2025 | Allow | 2 | 0 | 1 | Yes | No |
| 19063190 | COMPOSITIONS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND METHODS FOR MAKING AND USING THE SAME | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19046824 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING | February 2025 | May 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 19043567 | HUMANIZED ANTI-TISSUE FACTOR ANTIBODY, ANTIBODY-DRUG CONJUGATE PREPARED THEREFROM AND USE THEREOF | February 2025 | June 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19036915 | ANTIBODIES THAT BIND TNFRSF25 | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19033679 | ANTIBODIES TARGETING IL3 | January 2025 | May 2025 | Allow | 4 | 1 | 1 | No | No |
| 19032739 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19032782 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19026296 | MRNA VACCINE ENCODING FUSION ANTIGEN AGAINST MPOX AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19003301 | BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 AND BCMA | December 2024 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18999710 | ANTI-FUNGAL VHH ANTIBODIES | December 2024 | May 2025 | Allow | 4 | 1 | 0 | No | No |
| 18991315 | Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof | December 2024 | March 2025 | Allow | 3 | 1 | 0 | No | No |
| 18988307 | HUMANIZED ANTIBODIES AGAINST IRHOM2 | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18987178 | ANTI-CD161 ANTIBODIES AND USES THEREOF | December 2024 | February 2025 | Allow | 2 | 0 | 0 | No | No |
| 18988612 | SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATION | December 2024 | April 2025 | Allow | 4 | 1 | 0 | No | No |
| 18984595 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | December 2024 | July 2025 | Allow | 6 | 2 | 0 | No | No |
| 18980920 | FCRN/HSA BINDING MOLECULES AND METHODS OF USE | December 2024 | May 2025 | Allow | 5 | 0 | 1 | No | No |
| 18979795 | ANTIBODIES THAT BIND INTERLEUKIN 13 AND METHODS OF USE | December 2024 | May 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18977144 | NOVEL ANTIGEN BINDING MOLECULE FORMATS | December 2024 | April 2025 | Allow | 4 | 1 | 0 | No | No |
| 18962263 | ANTI-S100A4 HUMANIZED ANTIBODIES, USES AND METHODS | November 2024 | April 2025 | Allow | 4 | 1 | 1 | No | No |
| 18945784 | Antibodies Targeting ActRIIA and ActRIIB | November 2024 | February 2025 | Allow | 3 | 1 | 0 | No | No |
| 18944516 | BACILLUS STRAINS FOR IMPROVING FEED CONVERSION RATES AND BODY WEIGHT GAIN IN ANIMALS | November 2024 | June 2025 | Allow | 7 | 1 | 0 | No | No |
| 18940209 | METHOD OF USING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY TO DELIVER AN OLIGONUCLEOTIDE TO A SUBJECT HAVING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | November 2024 | March 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18939894 | COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF DELIVERING OLIGONUCLEOTIDE TO A SUBJECT | November 2024 | April 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18927497 | POLYPEPTIDE COMPRISING A SINGLE-DOMAIN ANTIBODY VARIABLE REGION THAT BINDS DELTA-LIKE LIGAND 3 (DLL3) AND METHOD OF USE THEREOF TO MAKE A RADIONUCLIDE COMPLEX | October 2024 | April 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18924707 | VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION | October 2024 | February 2025 | Allow | 4 | 1 | 0 | No | No |
| 18923463 | POLYNUCLEOTIDES ENCODING PARAOXONASE FUSION POLYPEPTIDES | October 2024 | December 2024 | Allow | 1 | 0 | 0 | No | No |
| 18922371 | METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY | October 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18920412 | ANTI-PHOSPHOCHOLINE ANTIBODIES AND METHODS OF USE THEREOF | October 2024 | March 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 18919069 | ANTIGEN BINDING POLYPEPTIDES | October 2024 | January 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18919082 | COMPOSITIONS FOR TREATING CANCER | October 2024 | June 2025 | Allow | 8 | 1 | 1 | No | No |
| 18911506 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | October 2024 | January 2025 | Allow | 4 | 1 | 0 | No | No |
| 18910549 | Humanized Anti-DNAM-1 Antibody | October 2024 | March 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18910550 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | October 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18907087 | BINDING AGENTS AND METHODS OF USING THE SAME | October 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18906588 | TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEM | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18905034 | TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE | October 2024 | April 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 18904628 | ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD | October 2024 | July 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18898854 | Antibodies Targeting ActRIIA and ActRIIB | September 2024 | December 2024 | Abandon | 3 | 0 | 0 | No | No |
| 18897951 | BISPECIFIC ANTIBODIES TARGETING PD1 AND VEGF | September 2024 | June 2025 | Allow | 8 | 1 | 0 | No | No |
| 18895539 | HEPARANASE-NEUTRALIZING A54 MONOCLONAL ANTIBODY | September 2024 | June 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18895456 | LACTIPLANTIBACILLUS PLANTARUM EFFECTIVELY INHIBITING MULTI-DRUG-RESISTANT KLEBSIELLA PNEUMONIAE AND USE THEREOF | September 2024 | January 2025 | Allow | 4 | 1 | 0 | No | No |
| 18896098 | ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUND | September 2024 | March 2025 | Allow | 5 | 1 | 0 | No | No |
| 18896799 | METHOD OF TREATING AN INTERLEUKIN-11-ASSOCIATED OR -MEDIATED FIBROTIC DISEASE OR CONDITION BY ADMINISTERING AN ANTI-INTERLEUKIN-11 RECEPTOR SUBUNIT ALPHA (IL-11RA) ANTIBODY | September 2024 | March 2025 | Allow | 6 | 1 | 1 | No | No |
| 18850224 | PEPTIDE USEFUL FOR THE TRANSPORT OF MOLECULES THROUGH CELL BARRIERS | September 2024 | June 2025 | Allow | 9 | 1 | 0 | No | No |
| 18890453 | ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION | September 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18887598 | ANTIBODIES SPECIFICALLY BINDING TO CD147 AND USES THEREOF | September 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18883719 | COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS | September 2024 | January 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18826183 | FUSION PROTEINS FOR IMMUNOTHERAPY AGAINST CANCER AND INFECTIOUS DISEASES | September 2024 | June 2025 | Allow | 9 | 1 | 0 | No | No |
| 18825396 | MICROBIAL COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | September 2024 | February 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18821737 | IMMUNOCONJUGATES AND METHODS | August 2024 | December 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18821730 | IMMUNOCONJUGATES AND METHODS | August 2024 | December 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18821707 | IMMUNOCONJUGATES AND METHODS | August 2024 | December 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18821718 | IMMUNOCONJUGATES AND METHODS | August 2024 | December 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18821883 | ENTERIC AEROBIZATION THERAPY | August 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18817152 | PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOF | August 2024 | May 2025 | Allow | 9 | 1 | 1 | No | No |
| 18815390 | FUSION PROTEIN COMPRISING ANTI-CD73 ANTIBODY AND IL-2, AND USE THEREOF | August 2024 | May 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18810381 | METHODS USING FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR RESTORING HEMOSTASIS IN A SUBJECT | August 2024 | February 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18810362 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6 | August 2024 | May 2025 | Allow | 8 | 2 | 0 | No | No |
| 18809763 | STRAIN OF LACTOBACILLUS HELVETICUS CAPABLE OF REMOVING MULTIPLE HEAVY METALS AND APPLICATION THEREOF IN GOAT MILK POWDER | August 2024 | March 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18807087 | DIMERIC ANTIBODIES | August 2024 | May 2025 | Allow | 9 | 2 | 0 | No | No |
| 18807097 | METHODS OF MANUFACTURING DIMERIC ANTIBODIES | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18805883 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18805937 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18802353 | COMPOUND COMPRISING FC-BINDING UNIT, AND CONJUGATE PREPARED USING SAME | August 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18799714 | RELAXIN-2 FUSION PROTEINS | August 2024 | February 2025 | Allow | 6 | 0 | 1 | No | No |
| 18793279 | ANTIBODIES TARGETING CCR2 | August 2024 | September 2024 | Allow | 2 | 0 | 0 | No | No |
| 18792921 | IgE BINDING PROTEINS AND USES THEREOF | August 2024 | December 2024 | Allow | 5 | 0 | 1 | Yes | No |
| 18787340 | LIVE TESTS FOR DIAGNOSIS OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY IN ANIMALS AND HUMANS | July 2024 | April 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18787110 | IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOF | July 2024 | April 2025 | Allow | 9 | 2 | 1 | No | No |
| 18777688 | METHOD FOR IMPROVING CELL ADHESION WITH SMECTITE CLAY | July 2024 | October 2024 | Allow | 2 | 1 | 0 | No | No |
| 18777712 | CELL ADHESION METHOD WITH SODIUM MONTMORILLONITE | July 2024 | September 2024 | Allow | 2 | 1 | 0 | No | No |
| 18777706 | METHOD OF INCREASING CELL ADHESION WITH PALYGORSKITE | July 2024 | September 2024 | Allow | 2 | 1 | 0 | No | No |
| 18774608 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | July 2024 | January 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18774646 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | July 2024 | April 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18774629 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | July 2024 | March 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18774123 | DOSING REGIMEN FOR TREATING INFLAMMATORY BOWEL DISEASE | July 2024 | April 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18773400 | VIVO GENE THERAPY USING INTRAOSSEOUS DELIVERY OF A LENTIVIRALGENE CONSTRUCT | July 2024 | June 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18772062 | TMEM219 ANTIBODIES AND THERAPEUTIC USES THEREOF | July 2024 | October 2024 | Allow | 3 | 1 | 0 | No | No |
| 18770102 | PHOSPHO-TAU ANTIBODIES AND METHODS OF USE | July 2024 | March 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18768336 | DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS | July 2024 | February 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 18768920 | BACILLUS VELEZENSIS COMPOSITIONS AND METHODS OF USE THEREOF | July 2024 | February 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18763332 | MITIGATION OF CRYPTOSPORIDIOSIS USING HYDROGEN PEROXIDE-GENERATING COMPOSITIONS | July 2024 | March 2025 | Allow | 8 | 0 | 0 | No | No |
| 18759723 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | June 2024 | December 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18759724 | COMPOSITIONS COMPRISING PLN-TARGETING ANTI-TRANSFERRIN RECEPTOR ANTIBODY-POLYNUCLEOTIDES AND METHODS OF USE THEREOF TO TREAT CARDIOMYOPATHY | June 2024 | June 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18755457 | ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4 | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18754918 | IMMUNOREACTIVE PEPTIDES | June 2024 | October 2024 | Allow | 3 | 0 | 1 | No | No |
| 18750999 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | June 2025 | Abandon | 12 | 0 | 1 | No | No |
| 18750887 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | June 2025 | Abandon | 12 | 0 | 1 | No | No |
| 18750908 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | April 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18749771 | COMPOSITIONS AND METHODS FOR DETECTING PANCREATIC CANCER | June 2024 | June 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18749504 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18749522 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18747102 | MULTIVALENT AND BISPECIFIC ANTIBODY CONSTRUCTS AND METHODS OF USE THEREOF | June 2024 | March 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18745750 | ANTI-RECEPTOR EXPRESSED ON LYMPHOID TISSUES (RELT) RECOMBINANT MONOCLONAL ANTIBODY AND PREPARATION METHOD AND USE THEREOF | June 2024 | November 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18744293 | METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIES | June 2024 | December 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18742215 | METHOD FOR MAKING PLURIPOTENT STEM CELLS | June 2024 | September 2024 | Allow | 3 | 0 | 0 | No | No |
| 18741232 | PURIFIED CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAE | June 2024 | June 2025 | Allow | 12 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1640.
With a 29.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Group 1640 is part of Technology Center 1600. This group has examined 104,190 patent applications in our dataset, with an overall allowance rate of 55.1%. Applications typically reach final disposition in approximately 33 months.
Applications in Group 1640 receive an average of 1.88 office actions before reaching final disposition. The median prosecution time is 33 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.